Literature DB >> 10611472

Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes.

S K Mishra1, P I Aaronson.   

Abstract

Thiazolidinediones are insulin-sensitising agents effective in controlling type II diabetes. These compounds also cause vasodilation. We evaluated the effects of the thiazolidinediones troglitazone and rosiglitazone on the glibenclamide-sensitive K(+) current in freshly isolated rat aorta myocytes. Troglitazone inhibited this current in a concentration-dependent manner (IC(50) approximately 1 microM). Rosiglitazone had a similar, but much less potent (IC(50) approximately 20 microM) action. Block of the glibenclamide-sensitive K(+) channels, in particular by troglitazone, may potentially affect the response of arteries to hypoxia and to certain endogenous and exogenous vasodilators.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611472     DOI: 10.1016/s0014-2999(99)00713-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.

Authors:  Lei Yu; Xin Jin; Yang Yang; Ningren Cui; Chun Jiang
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

2.  Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.

Authors:  Lei Yu; Xin Jin; Ningren Cui; Yang Wu; Zhenda Shi; Daling Zhu; Chun Jiang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation.

Authors:  I Jeong; B H Choi; S J Hahn
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.

Authors:  N Szentandrássy; G Harmati; L Bárándi; J Simkó; B Horváth; J Magyar; T Bányász; I Lorincz; A Szebeni; V Kecskeméti; P P Nánási
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

5.  Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels.

Authors:  Yasser Majeed; Yahya Bahnasi; Victoria A L Seymour; Lesley A Wilson; Carol J Milligan; Anil K Agarwal; Piruthivi Sukumar; Jacqueline Naylor; David J Beech
Journal:  Mol Pharmacol       Date:  2011-03-15       Impact factor: 4.436

6.  Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

Authors:  A Szebeni; N Szentandrássy; P Pacher; J Simkó; P P Nánási; V Kecskeméti
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.